期刊
BRITISH JOURNAL OF CANCER
卷 103, 期 11, 页码 1692-1697出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/sj.bjc.6605952
关键词
mesenchymal stem cell; cancer stem cell; side population; lung cancer; TRAIL; apoptosis
类别
资金
- Department of Health's NIHR Biomedical Research Centre
- MRC [G108/596, G0501781, G1000355] Funding Source: UKRI
- Medical Research Council [G0501781, G108/596, G1000355] Funding Source: researchfish
BACKGROUND: Tumours contain stem-like, side population (SP) cells, which have increased tumorigenic potential, resistance to traditional therapies and may be responsible for treatment failures and relapse in patients. METHODS: Mesenchymal stem cells (MSCs) were engineered to express the apoptotic ligand, TNF-related apoptosis-inducing ligand (TRAIL). Squamous (H357) and lung (A549) cancer cell lines were sorted into side and non-side populations (non-SP) by Hoechst flow cytometry. The survival and growth of both SP and non-SP cancer populations, in conjunction with TRAIL-expressing MSCs and mitoxantrone chemotherapy, were assessed by flow cytometry and colony forming ability. RESULTS: Mesenchymal stem cells expressing TRAIL migrate to tumours and reduce the growth of primary cancers and metastases. This report demonstrates that these cells cause apoptosis, death and reduced colony formation of the SP of squamous and adenocarcinoma lung cancer cells and are synergistic when combined with traditional chemotherapy in apoptosis induction. CONCLUSIONS: The sensitivity of putative cancer stem cells to TRAIL-expressing MSCs, suggests their possible role in the prevention of cancer relapse. British Journal of Cancer (2010) 103, 1692-1697. doi:10.1038/sj.bjc.6605952 www.bjcancer.com Published online 9 November 2010 (C) 2010 Cancer Research UK
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据